Propanc Biopharma, Inc.
Propanc Biopharma, Inc. (PPCB) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
ppcb · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 5 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Propanc Biopharma, Inc.You PPCB | $1M | N/A | — | — |
 Cell Source, Inc. CLCS | $37M | N/A | — | -$0.11 |
 Gemina Laboratories Ltd. GLABF | $4M | N/A | — | -$0.03 |
 HOOKIPA Pharma Inc. HOOK | $14M | N/A | — | -$1.09 |
 EOM Pharmaceuticals Holdings, Inc. IMUC | $31M | N/A | — | -$0.02 |
 Quest PharmaTech Inc. QPTFF | $5M | 0.61x | — | $0.03 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Propanc Biopharma, Inc. (PPCB) measures how much investors pay for each dollar of the company's trailing earnings. PPCB's current PE ratio of N/A is calculated by dividing its stock price of $1.42 by its TTM earnings per share of —.
Frequently asked questions
PPCB pe ratio · 6 questionsPPCB's current PE ratio is N/A as of 2026-06-09, based on a stock price of $1.42 and TTM EPS of —. Data sourced from Financial Modeling Prep via PPCB's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Propanc Biopharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09